drugset / Trial / NCT01571167
Varenicline as a Treatment for Methamphetamine Dependence
Phase 1
Completed
17 enrolled
Baylor College of Medicine
National Institute on Drug Abuse (NIDA) · collab
RandomizedCrossoverQuadruple-blind
Summary
The primary purpose of the study is to determine the effects of treatment with varenicline (1 and 2 mg daily), compared to treatment with placebo, on methamphetamine-induced craving and subjective effects in methamphetamine-dependent human volunteers.
Timeline
- Start
- 2011-01
- Primary completion
- 2012-02
- Completion
- 2012-02
Publications
- Kalechstein AD, Mahoney JJ 3rd, Verrico CD, De La Garza R 2nd. Short-term, low-dose varenicline administration enhances information processing speed in methamphetamine-dependent users. Neuropharmacology. 2014 Oct;85:493-8. doi: 10.1016/j.neuropharm.2014.05.045. Epub 2014 Jun 12.
- Verrico CD, Mahoney JJ 3rd, Thompson-Lake DG, Bennett RS, Newton TF, De La Garza R 2nd. Safety and efficacy of varenicline to reduce positive subjective effects produced by methamphetamine in methamphetamine-dependent volunteers. Int J Neuropsychopharmacol. 2014 Feb;17(2):223-33. doi: 10.1017/S146114571300134X.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Varenicline | Small molecule | 1 mg | Oral |
| Comparator | Varenicline | Small molecule | 2 mg | Oral |